Update on the Pharmacokinetic Aspects of Antiretroviral Agents: Implications in Therapeutic Drug Monitoring

Title: Update on the Pharmacokinetic Aspects of Antiretroviral Agents: Implications in Therapeutic Drug Monitoring

Volume: 12 Issue: 9

Author(s): J. C. Slish, L. M. Catanzaro, Q. Ma, O. O. Okusanya, L. Demeter, M. Albrecht and G. D. Morse

Affiliation:

Keywords: HIV enteropathy, P-glycoprotein, CXCR4 inhibitors, CYP450 system, HIV-1 protease inhibitors (PIs), adherence

Abstract: The observed inter-individual variation in antiretroviral pharmacokinetics (PK) that results in a wide range of drug exposures from fixed-dose regimens has led to increasing interest in the clinical use of therapeutic drug monitoring (TDM) to individualize dosing of antiretroviral therapy (ART). The focus of this review is to provide an overview of literature available to support therapeutic drug monitoring among the current classes of antiretrovirals, suggest patient populations that may benefit from TDM and bring forth some of the limitations that may exist for widespread use of TDM in a traditional clinical setting.

Cite this article as:

Slish C. J., Catanzaro M. L., Ma Q., Okusanya O. O., Demeter L., Albrecht M. and Morse D. G., Update on the Pharmacokinetic Aspects of Antiretroviral Agents: Implications in Therapeutic Drug Monitoring, Current Pharmaceutical Design 2006; 12 (9) . https://dx.doi.org/10.2174/138161206776055787